Russ Conroy

Updated results from the phase 3 CheckMate 9ER trial continue to support nivolumab plus cabozantinib as a first-line treatment for patients with advanced or metastatic renal cell carcinoma.

Data from the European phase 1 MB-105 trial indicate that the safety profile of annamycin in geriatric advance acute myeloid leukemia are consistent with previously reported findings.

Adverse effects including light sensitivity and blurred vision lead to a clinical hold in enrollment for the phase 1/2 VERA trial evaluating BLU-222 in advanced solid tumors.

The investigational CAR T-cell therapy equecabtagene autoleucel receives fast track and regenerative medicine advanced therapy designations for managing relapsed or refractory multiple myeloma.

Data from the phase 3 ROMAN trial and the phase 2b GT-201 trial support the new drug application for avasopasem in radiotherapy-induced severe oral mucositis for those with head and neck cancer.

Patients 70 years or older with limited stage small cell lung cancer appear to tolerate concurrent thoracic chemoradiotherapy and have similar disease control rates as younger patients.

Although trilaciclib appears to reduce neutropenia following treatment with FOLFOXIRI and bevacizumab in patients with metastatic colorectal cancer, the phase 3 PRESERVE 1 trial will be stopped due to a lack of responses.

The FDA gives orphan drug designation to ezurpimtrostat, an investigational autophagy inhibitor that may benefit patients with hepatocellular carcinoma.

The addition of everolimus to vorolanib appears to improve outcomes in metastatic renal cell carcinoma.

Real-world findings from an observational study indicate that bendamustine plus rituximab appears to be well tolerated by elderly patients with transplant-ineligible mantle cell lymphoma and indolent non-Hodgkin lymphoma.

CAR T-cell therapy brexucabtagene autoleucel appears to produce an overall survival benefit among patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Data from a retrospective study suggests that stereotactic body radiotherapy may be a suitable alternative to surgical resection for patients with primary lung neuroendocrine tumors, according to an expert from Moffitt Cancer Center.

Investigators identify an association between circulating tumor DNA in the blood plasma detected via the RaDaR assay and response to treatment with neoadjuvant immunotherapy for muscle-invasive bladder cancer.

Findings from the phase 2 TELMA trial suggest that atezolizumab plus bevacizumab yields robust, long-lasting outcomes for patients with metastatic nonsquamous tumor mutational burden–high non–small cell lung cancer.

Findings from a randomized trial indicate that therapeutic education plus physical activity are safe, feasible, and potentially effective for patients with hematologic cancer.

A biologic license application for a biosimilar of denosumab is under review by the FDA for managing osteoporosis and treatment-induced bone loss in those with cancer.

Findings from a study indicate that measurable residual disease clearance is associated with favorable outcomes in acute myeloid leukemia following subsequent therapy before allogenic stem cell transplant.

The FDA gives orphan drug designation to BEA-17, an investigational small molecule degrader that may benefit those with a common and aggressive brain tumor.

A biologic license application that has been resubmitted to the FDA for remestemcel-L in pediatric graft-versus-host disease includes new long-term survival data from a phase 3 clinical trial.

According to findings from a phase 2 clinical study, futibatinib may achieve benefit in patients with intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements.

Pembrolizumab plus chemotherapy appears to produce a significant improvement in progression-free survival among patients with advanced or recurrent endometrial cancer.

Patients with pre-treated, unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer can now receive treatment with sacituzumab govitecan following approval from the FDA.

Data from the final analysis of the phase 3 KEYNOTE-966 trial indicate that pembrolizumab plus chemotherapy yields improvements in overall survival compared with chemotherapy alone in patients with advanced biliary tract cancer.

The FDA gives orphan drug exclusivity to sodium phosphate injection for the prevention of cisplatin-related hearing loss in pediatric patients 1 month and older with localized, non-metastatic solid tumors.

Findings from a randomized clinical trial suggest that tele-cognitive behavioral therapy may help reduce body image distress among survivors of head and neck cancer.

Investigators will evaluate DK210 in a first-in-human phase 1 clinical trial following the FDA’s review of an investigational new drug application for the compound for locally advanced or metastatic EGFR-positive solid tumors.

Results from the phase 1/2 CodeBreaK 100 trial indicate that sotorasib yields positive anticancer activity and safety in patients with pancreatic cancer harboring KRAS p.G12C mutations.

Investigators say that a phase 1/2 trial evaluating MGTA-117 in 2 hematologic malignancies has been paused following a serious adverse effect that may be related to the agent.

Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer can now receive elacestrant as treatment following the FDA’s approval of the agent.

The approval for pirtobrutinib in the treatment of patients with relapsed or refractory mantle cell lymphoma was based on data from the phase 1/2 BRUIN trial.